MOLECULAR-GENETIC MARKERS OF RESPONSE TO NEOADJUVANT CHEMOTHERAPY WITH ANTHRACYCLINES IN BREAST CANCER PATIENTS
The purpose of the study: to evaluate the response to neoadjuvant anthracycline-based chemotherapy depending on the presence of deletions and amplifications of different chromosomal loci and the expression level of topoisomerase 2а in tumor tissue of breast cancer patients. Materials and methods. Th...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Russian Academy of Sciences, Tomsk National Research Medical Center
2016-07-01
|
| Series: | Сибирский онкологический журнал |
| Subjects: | |
| Online Access: | https://www.siboncoj.ru/jour/article/view/330 |
| _version_ | 1797875863124967424 |
|---|---|
| author | P. V. Kazantseva М. М. Tsyganov Е. М. Slonimskaya N. V. Litvyakov Н. В. Cherdyntseva М. K. Ibragimova А. V. Doroshenko N. А. Tarabanovskaya S. V. Patalyak |
| author_facet | P. V. Kazantseva М. М. Tsyganov Е. М. Slonimskaya N. V. Litvyakov Н. В. Cherdyntseva М. K. Ibragimova А. V. Doroshenko N. А. Tarabanovskaya S. V. Patalyak |
| author_sort | P. V. Kazantseva |
| collection | DOAJ |
| description | The purpose of the study: to evaluate the response to neoadjuvant anthracycline-based chemotherapy depending on the presence of deletions and amplifications of different chromosomal loci and the expression level of topoisomerase 2а in tumor tissue of breast cancer patients. Materials and methods. The study included 46 patients with stage T2–4N0–3M0 breast cancer, who received 2–6 cycles of neoadjuvant chemotherapy with FAC and CAX regimens. Results. The relationship between the expression level of Тор2а>5, deletions of ABCB1, ABCB3, 18р11.21, 11q22.1 loci and amplification of 1q24.1-43 and the response to preoperative treatment was found. Of the 34 patients having at least one of these markers in the tumor tissue, 85.3 % of them demonstrated partial response to neoadjuvant chemotherapy (> 50 % reduction of tumor) and 14.7 % had stable disease and disease progression. No above markers were found in the tumor tissue of 12 patients, who did not respond to preoperative treatment. Conclusion. High levels of Тор2а>5 expression, deletions of ABCB1; ABCB3; 18р11.21; 11q22.1 loci and 1q24.1-43 amplification were shown to be predictive markers of response to neoadjuvant anthracycline-based chemotherapy. The presence of at least one of these markers allowed us to predict response to preoperative treatment in 85 % of cases. |
| first_indexed | 2024-04-10T01:54:17Z |
| format | Article |
| id | doaj.art-73a6c4389f624e60ada679aab11c28e7 |
| institution | Directory Open Access Journal |
| issn | 1814-4861 2312-3168 |
| language | Russian |
| last_indexed | 2024-04-10T01:54:17Z |
| publishDate | 2016-07-01 |
| publisher | Russian Academy of Sciences, Tomsk National Research Medical Center |
| record_format | Article |
| series | Сибирский онкологический журнал |
| spelling | doaj.art-73a6c4389f624e60ada679aab11c28e72023-03-13T09:05:49ZrusRussian Academy of Sciences, Tomsk National Research Medical CenterСибирский онкологический журнал1814-48612312-31682016-07-01152293510.21294/1814-4861-2016-15-2-29-35323MOLECULAR-GENETIC MARKERS OF RESPONSE TO NEOADJUVANT CHEMOTHERAPY WITH ANTHRACYCLINES IN BREAST CANCER PATIENTSP. V. Kazantseva0М. М. Tsyganov1Е. М. Slonimskaya2N. V. Litvyakov3Н. В. Cherdyntseva4М. K. Ibragimova5А. V. Doroshenko6N. А. Tarabanovskaya7S. V. Patalyak8Томский НИИ онкологии, 634009, г. Томск, пер. Кооперативный, 5Томский НИИ онкологии, 634009, г. Томск, пер. Кооперативный, 5; Национальный исследовательский Томский государственный университет, г. ТомскТомский НИИ онкологии, 634009, г. Томск, пер. Кооперативный, 5; ГБОУ ВПО «Сибирский государственный медицинский университет» Минздрава России, г. ТомскТомский НИИ онкологии, 634009, г. Томск, пер. Кооперативный, 5; Национальный исследовательский Томский государственный университет, г. ТомскТомский НИИ онкологии, 634009, г. Томск, пер. Кооперативный, 5Томский НИИ онкологии, 634009, г. Томск, пер. Кооперативный, 5; Национальный исследовательский Томский государственный университет, г. ТомскТомский НИИ онкологии, 634009, г. Томск, пер. Кооперативный, 5Томский НИИ онкологии, 634009, г. Томск, пер. Кооперативный, 5Томский НИИ онкологии, 634009, г. Томск, пер. Кооперативный, 5The purpose of the study: to evaluate the response to neoadjuvant anthracycline-based chemotherapy depending on the presence of deletions and amplifications of different chromosomal loci and the expression level of topoisomerase 2а in tumor tissue of breast cancer patients. Materials and methods. The study included 46 patients with stage T2–4N0–3M0 breast cancer, who received 2–6 cycles of neoadjuvant chemotherapy with FAC and CAX regimens. Results. The relationship between the expression level of Тор2а>5, deletions of ABCB1, ABCB3, 18р11.21, 11q22.1 loci and amplification of 1q24.1-43 and the response to preoperative treatment was found. Of the 34 patients having at least one of these markers in the tumor tissue, 85.3 % of them demonstrated partial response to neoadjuvant chemotherapy (> 50 % reduction of tumor) and 14.7 % had stable disease and disease progression. No above markers were found in the tumor tissue of 12 patients, who did not respond to preoperative treatment. Conclusion. High levels of Тор2а>5 expression, deletions of ABCB1; ABCB3; 18р11.21; 11q22.1 loci and 1q24.1-43 amplification were shown to be predictive markers of response to neoadjuvant anthracycline-based chemotherapy. The presence of at least one of these markers allowed us to predict response to preoperative treatment in 85 % of cases.https://www.siboncoj.ru/jour/article/view/330рак молочной железынеоадъювантная химиотерапияпредсказательные критерииуровень экспрессии тор2аделеция генов авс-транспортеровcnv днк опухоли |
| spellingShingle | P. V. Kazantseva М. М. Tsyganov Е. М. Slonimskaya N. V. Litvyakov Н. В. Cherdyntseva М. K. Ibragimova А. V. Doroshenko N. А. Tarabanovskaya S. V. Patalyak MOLECULAR-GENETIC MARKERS OF RESPONSE TO NEOADJUVANT CHEMOTHERAPY WITH ANTHRACYCLINES IN BREAST CANCER PATIENTS Сибирский онкологический журнал рак молочной железы неоадъювантная химиотерапия предсказательные критерии уровень экспрессии тор2а делеция генов авс-транспортеров cnv днк опухоли |
| title | MOLECULAR-GENETIC MARKERS OF RESPONSE TO NEOADJUVANT CHEMOTHERAPY WITH ANTHRACYCLINES IN BREAST CANCER PATIENTS |
| title_full | MOLECULAR-GENETIC MARKERS OF RESPONSE TO NEOADJUVANT CHEMOTHERAPY WITH ANTHRACYCLINES IN BREAST CANCER PATIENTS |
| title_fullStr | MOLECULAR-GENETIC MARKERS OF RESPONSE TO NEOADJUVANT CHEMOTHERAPY WITH ANTHRACYCLINES IN BREAST CANCER PATIENTS |
| title_full_unstemmed | MOLECULAR-GENETIC MARKERS OF RESPONSE TO NEOADJUVANT CHEMOTHERAPY WITH ANTHRACYCLINES IN BREAST CANCER PATIENTS |
| title_short | MOLECULAR-GENETIC MARKERS OF RESPONSE TO NEOADJUVANT CHEMOTHERAPY WITH ANTHRACYCLINES IN BREAST CANCER PATIENTS |
| title_sort | molecular genetic markers of response to neoadjuvant chemotherapy with anthracyclines in breast cancer patients |
| topic | рак молочной железы неоадъювантная химиотерапия предсказательные критерии уровень экспрессии тор2а делеция генов авс-транспортеров cnv днк опухоли |
| url | https://www.siboncoj.ru/jour/article/view/330 |
| work_keys_str_mv | AT pvkazantseva moleculargeneticmarkersofresponsetoneoadjuvantchemotherapywithanthracyclinesinbreastcancerpatients AT mmtsyganov moleculargeneticmarkersofresponsetoneoadjuvantchemotherapywithanthracyclinesinbreastcancerpatients AT emslonimskaya moleculargeneticmarkersofresponsetoneoadjuvantchemotherapywithanthracyclinesinbreastcancerpatients AT nvlitvyakov moleculargeneticmarkersofresponsetoneoadjuvantchemotherapywithanthracyclinesinbreastcancerpatients AT nvcherdyntseva moleculargeneticmarkersofresponsetoneoadjuvantchemotherapywithanthracyclinesinbreastcancerpatients AT mkibragimova moleculargeneticmarkersofresponsetoneoadjuvantchemotherapywithanthracyclinesinbreastcancerpatients AT avdoroshenko moleculargeneticmarkersofresponsetoneoadjuvantchemotherapywithanthracyclinesinbreastcancerpatients AT natarabanovskaya moleculargeneticmarkersofresponsetoneoadjuvantchemotherapywithanthracyclinesinbreastcancerpatients AT svpatalyak moleculargeneticmarkersofresponsetoneoadjuvantchemotherapywithanthracyclinesinbreastcancerpatients |